TAK1 signaling in fibrosis: insights from systemic sclerosis
- 1Department of Research and Development, Eydis Bio Inc.
- 2Michigan Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan
Abstract
Systemic sclerosis (SSc) is a complex autoimmune disease characterized by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. Widespread and recalcitrant fibrosis underlies the significant morbidity and mortality of SSc. TGF-β-activated kinase 1 (TAK1), a key regulator of various cellular processes including inflammation and fibrosis has emerged as a pivotal player in the pathogenesis of fibrotic diseases such as SSc. This timely review explores the biology and multifaceted roles of TAK1 in SSc, encompassing its involvement in fibroblast activation, immune cell function, and endothelial dysfunction. Mechanistically, TAK1 integrates signals from diverse cytokines and growth factors to modulate downstream effectors such as NF-κB and MAP kinases, thereby influencing inflammation, oxidative stress, and tissue remodeling in SSc. Notably, dysregulation of TAK1 signaling pathways has been implicated in the aberrant activation of fibroblasts and the persistence of profibrotic responses characteristic of SSc. Understanding the intricate network of TAK1-mediated intracellular signaling pathways offers new insights into potential therapeutic strategies targeting this kinase for the treatment of SSc and fibrosis. This review synthesizes current knowledge and highlights promising avenues for future research aimed at harnessing TAK1 as a therapeutic target in SSc management.
Related
- A mast cell receptor is associated with fibrosis and itch in systemic sclerosis
- The Edwardsiella T3SS effector EseJ enhances NF-κB signaling by stabilizing p65 and promoting TAK1 phosphorylation
- Salivary gland and hand involvement in Systemic sclerosis: A cross-sectional ultrasound and radiographic study.
- Spatial proteomic profiling of cardiac stromal populations and microenvironments in systemic sclerosis-associated primary myocardial involvement
- Thrombotic microangiopathy in a patient with systemic lupus erythematosus and systemic sclerosis overlap syndrome: a case report and review of the literature
BibTeX
@article{scarneo2026tak1,
title = {{TAK1 signaling in fibrosis: insights from systemic sclerosis}},
author = {Scott Scarneo and Robert Freeze and Swati Bhattacharyya and John Varga},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1960713},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1960713/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - TAK1 signaling in fibrosis: insights from systemic sclerosis
AU - Scott Scarneo
AU - Robert Freeze
AU - Swati Bhattacharyya
AU - John Varga
PY - 2026
DA - 2026/10/19
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1960713
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1960713/full
AB - Systemic sclerosis (SSc) is a complex autoimmune disease characterized by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. Widespread and recalcitrant fibrosis underlies the significant morbidity and mortality of SSc. TGF-β-activated kinase 1 (TAK1), a key regulator of various cellular processes including inflammation and fibrosis has emerged as a pivotal player in the pathogenesis of fibrotic diseases such as SSc. This timely review explores the biology and multifaceted roles of TAK1 in SSc, encompassing its involvement in fibroblast activation, immune cell function, and endothelial dysfunction. Mechanistically, TAK1 integrates signals from diverse cytokines and growth factors to modulate downstream effectors such as NF-κB and MAP kinases, thereby influencing inflammation, oxidative stress, and tissue remodeling in SSc. Notably, dysregulation of TAK1 signaling pathways has been implicated in the aberrant activation of fibroblasts and the persistence of profibrotic responses characteristic of SSc. Understanding the intricate network of TAK1-mediated intracellular signaling pathways offers new insights into potential therapeutic strategies targeting this kinase for the treatment of SSc and fibrosis. This review synthesizes current knowledge and highlights promising avenues for future research aimed at harnessing TAK1 as a therapeutic target in SSc management.
SN - 1664-3224
ER -